Regulus Therapeutics

Regulus Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. They believe that targeting RNA biology with antisense oligonucleotides offers a novel and potentially powerful therapeutic approach for a wide range of diseases. Their primary focus is on orphan kidney diseases, specifically Autosomal Dominant Polycystic Kidney Disease (ADPKD), where microRNA genetic drivers are implicated and there are significant unmet medical needs.

Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline of microRNA-based therapeutics. They are advancing their next-generation, anti-miR-17 compound, RGLS8429, to treat ADPKD, building upon positive clinical results seen with their first-generation compound. They are currently evaluating RGLS8429 in a Phase 1b clinical trial, aiming to demonstrate its effectiveness and safety in patients with ADPKD.

Regulus Therapeutics offers a competitive benefits package that includes a choice of health, vision, and dental insurance, life insurance, flexible spending accounts, 401K plan, vacation and stock options. They believe in providing a work-life balance and support employees in creating the life and work style that brings their best to their community, family, and Regulus' mission. The majority of benefits become effective immediately on the date of hire without any pre-existing condition exclusion, although temporary employees, contractors, interns and co-ops are not eligible.

Regulus Therapeutics offers a competitive benefits package to its employees, including health, vision, and dental insurance, life insurance, flexible spending accounts, a 401(k) plan with a generous employer match, vacation time, and stock options. The company prioritizes employee well-being and provides resources to support a healthy work-life balance. Most benefits are effective immediately upon hire and extend to eligible dependents, including spouses or domestic partners and children up to age 26.

Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines that target microRNAs to treat genetically based orphan diseases. Their mission is to improve the lives of patients and their families by developing oligonucleotide therapeutics that inhibit dysregulated microRNA targets, particularly focusing on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs.

Regulus Therapeutics fosters a culture that values scientific rigor, creative problem-solving, collaboration across departments and disciplines, and persistence in the face of obstacles. They are passionate about the potential of their work to improve the lives of patients and their families, and this passion is reflected in their dedication to learning, growth, and serving the needs of those affected by genetic kidney diseases and other genetically-based orphan diseases.

Regulus Therapeutics is committed to fostering a culture of diversity, equity, and inclusion. They believe that a diverse workforce is essential to their success, and they actively seek out and hire individuals from all backgrounds and identities. They also strive to create an equitable and inclusive work environment where everyone feels valued, respected, and supported.